O	0	10	Randomized
O	11	21	Controlled
O	22	27	Trial
O	28	30	of
B-intervention	31	41	Zoledronic
I-intervention	42	46	Acid
I-intervention	47	51	plus
I-intervention	52	64	Chemotherapy
O	65	71	versus
B-control	72	84	Chemotherapy
I-control	85	90	Alone
O	91	93	as
O	94	105	Neoadjuvant
O	106	115	Treatment
O	116	118	of
O	119	123	HER2
O	123	124	-
O	124	132	Negative
O	133	140	Primary
O	141	147	Breast
O	148	154	Cancer
O	155	156	(
O	156	161	JONIE
O	162	167	Study
O	167	168	)
O	168	169	.

O	170	180	Zoledronic
O	181	185	acid
O	186	187	(
O	187	190	ZOL
O	190	191	)
O	192	194	is
O	195	196	a
O	197	205	nitrogen
O	205	206	-
O	206	216	containing
O	217	231	bisphosphonate
O	232	236	that
O	237	244	induces
O	245	255	osteoclast
O	256	265	apoptosis
O	266	269	and
O	270	278	inhibits
O	279	283	bone
O	284	294	resorption
O	295	297	by
O	298	308	inhibiting
O	309	312	the
O	313	323	mevalonate
O	324	331	pathway
O	331	332	.

O	333	336	Its
O	337	344	benefit
O	345	348	for
O	349	352	the
O	353	363	prevention
O	364	366	of
B-condition	367	375	skeletal
I-condition	376	389	complications
O	390	393	due
O	394	396	to
O	397	401	bone
O	402	412	metastases
O	413	416	has
O	417	421	been
O	422	433	established
O	433	434	.

O	435	442	However
O	442	443	,
O	444	447	the
O	448	457	antitumor
O	458	466	efficacy
O	467	469	of
O	470	473	ZOL
O	473	474	,
O	475	483	although
O	484	493	suggested
O	494	496	by
O	497	505	multiple
O	506	517	preclinical
O	518	521	and
O	522	530	clinical
O	531	538	studies
O	538	539	,
O	540	543	has
O	544	547	not
O	548	551	yet
O	552	556	been
O	557	567	clinically
O	568	574	proven
O	574	575	.

O	576	578	We
O	579	588	performed
O	589	592	the
O	593	600	present
O	601	611	randomized
O	612	617	Phase
O	618	619	2
O	620	625	trial
O	626	628	to
O	629	640	investigate
O	641	644	the
O	645	654	antitumor
O	655	661	effect
O	662	664	of
O	665	668	ZOL
O	669	673	with
O	674	686	chemotherapy
O	687	688	(
O	688	690	CT
O	690	691	)
O	691	692	.

B-ethinicity	693	698	Asian
B-eligibility	699	707	patients
I-eligibility	708	712	with
I-eligibility	713	717	HER2
I-eligibility	717	718	-
I-eligibility	718	726	negative
I-eligibility	727	735	invasive
I-eligibility	736	742	breast
I-eligibility	743	749	cancer
O	750	754	were
O	755	763	randomly
O	764	772	assigned
O	773	775	to
O	776	782	either
O	783	786	the
O	787	789	CT
O	790	792	or
O	793	795	CT
O	795	796	+
O	796	799	ZOL
O	800	801	(
O	801	804	CTZ
O	804	805	)
O	806	811	group
O	811	812	.

B-total-participants	813	816	One
I-total-participants	817	824	hundred
I-total-participants	825	828	and
I-total-participants	829	835	eighty
I-total-participants	835	836	-
I-total-participants	836	841	eight
O	842	850	patients
O	851	855	were
O	856	866	randomized
O	867	869	to
O	870	876	either
O	877	880	the
O	881	883	CT
O	884	889	group
O	890	891	(
O	891	892	n
O	893	894	=
B-control-participants	895	897	95
O	897	898	)
O	899	901	or
O	902	905	the
O	906	909	CTZ
O	910	915	group
O	916	917	(
O	917	918	n
O	919	920	=
B-intervention-participants	921	923	93
O	923	924	)
O	925	929	from
O	930	935	March
O	936	940	2010
O	941	943	to
O	944	949	April
O	950	954	2012
O	954	955	,
O	956	959	and
B-total-participants	960	963	180
O	964	972	patients
O	973	977	were
O	978	986	assessed
O	986	987	.

O	988	991	All
O	992	1000	patients
O	1001	1009	received
O	1010	1014	four
O	1015	1021	cycles
O	1022	1024	of
O	1025	1031	FEC100
O	1032	1033	(
O	1033	1045	fluorouracil
O	1046	1049	500
O	1050	1052	mg
O	1052	1053	/
O	1053	1055	m2
O	1055	1056	,
O	1057	1067	epirubicin
O	1068	1071	100
O	1072	1074	mg
O	1074	1075	/
O	1075	1077	m2
O	1077	1078	,
O	1079	1082	and
O	1083	1099	cyclophosphamide
O	1100	1103	500
O	1104	1106	mg
O	1106	1107	/
O	1107	1109	m2
O	1109	1110	)
O	1110	1111	,
O	1112	1120	followed
O	1121	1123	by
O	1124	1126	12
O	1127	1133	cycles
O	1134	1136	of
O	1137	1147	paclitaxel
O	1148	1150	at
O	1151	1153	80
O	1154	1156	mg
O	1156	1157	/
O	1157	1159	m2
O	1160	1166	weekly
O	1166	1167	.

O	1168	1171	ZOL
O	1172	1173	(
O	1173	1174	4
O	1175	1177	mg
O	1177	1178	)
O	1179	1182	was
O	1183	1195	administered
O	1196	1201	three
O	1202	1204	to
O	1205	1209	four
O	1210	1215	times
O	1216	1222	weekly
O	1223	1226	for
O	1227	1228	7
O	1229	1234	weeks
O	1235	1237	to
O	1238	1241	the
O	1242	1250	patients
O	1251	1253	in
O	1254	1257	the
O	1258	1261	CTZ
O	1262	1267	group
O	1267	1268	.

O	1269	1272	The
O	1273	1280	primary
O	1281	1289	endpoint
O	1290	1293	was
O	1294	1297	the
B-outcome-Measure	1298	1310	pathological
I-outcome-Measure	1311	1319	complete
I-outcome-Measure	1320	1328	response
I-outcome-Measure	1329	1330	(
I-outcome-Measure	1330	1333	pCR
I-outcome-Measure	1333	1334	)
I-outcome-Measure	1335	1339	rate
O	1339	1340	,
O	1341	1346	which
O	1347	1350	was
O	1351	1358	defined
O	1359	1361	as
O	1362	1364	no
O	1365	1373	invasive
O	1374	1380	cancer
O	1381	1383	in
O	1384	1387	the
O	1388	1394	breast
O	1395	1401	tissue
O	1402	1410	specimen
O	1410	1411	.

O	1412	1418	Safety
O	1419	1422	was
O	1423	1431	assessed
O	1432	1434	in
O	1435	1438	all
O	1439	1447	patients
O	1448	1451	who
O	1452	1460	received
O	1461	1463	at
O	1464	1469	least
O	1470	1473	one
O	1474	1478	dose
O	1479	1481	of
O	1482	1485	the
O	1486	1491	study
O	1492	1496	drug
O	1496	1497	.

O	1498	1502	This
O	1503	1513	randomized
O	1514	1524	controlled
O	1525	1530	trial
O	1531	1540	indicated
O	1541	1545	that
O	1546	1549	the
B-outcome	1550	1555	rates
I-outcome	1556	1558	of
I-outcome	1559	1562	pCR
O	1563	1565	in
O	1566	1569	CTZ
O	1570	1575	group
O	1576	1577	(
B-iv-bin-percent	1577	1579	14
I-iv-bin-percent	1579	1580	.
I-iv-bin-percent	1580	1581	8
I-iv-bin-percent	1581	1582	%
O	1582	1583	)
O	1584	1587	was
O	1588	1595	doubled
O	1596	1598	to
O	1599	1601	CT
O	1602	1607	group
O	1608	1609	(
B-cv-bin-percent	1609	1610	7
I-cv-bin-percent	1610	1611	.
I-cv-bin-percent	1611	1612	7
I-cv-bin-percent	1612	1613	%
O	1613	1614	)
O	1614	1615	,
O	1616	1628	respectively
O	1629	1630	(
O	1630	1633	one
O	1633	1634	-
O	1634	1639	sided
O	1640	1643	chi
O	1643	1644	-
O	1644	1650	square
O	1651	1655	test
O	1655	1656	,
O	1657	1658	p
O	1659	1660	=
O	1661	1662	0
O	1662	1663	.
O	1663	1666	068
O	1666	1667	)
O	1667	1668	,
O	1669	1675	though
O	1676	1679	the
O	1680	1690	additional
O	1691	1699	efficacy
O	1700	1702	of
O	1703	1713	zoledronic
O	1714	1718	acid
O	1719	1722	was
O	1723	1726	not
O	1727	1739	demonstrated
O	1740	1753	statistically
O	1753	1754	.

O	1755	1758	The
B-outcome	1759	1762	pCR
I-outcome	1763	1767	rate
I-outcome	1768	1770	in
I-outcome	1771	1785	postmenopausal
I-outcome	1786	1794	patients
O	1795	1798	was
B-iv-bin-percent	1799	1801	18
I-iv-bin-percent	1801	1802	.
I-iv-bin-percent	1802	1803	4
I-iv-bin-percent	1803	1804	%
O	1805	1808	and
B-cv-bin-percent	1809	1810	5
I-cv-bin-percent	1810	1811	.
I-cv-bin-percent	1811	1812	1
I-cv-bin-percent	1812	1813	%
O	1814	1816	in
O	1817	1820	the
O	1821	1824	CTZ
O	1825	1828	and
O	1829	1831	CT
O	1832	1838	groups
O	1838	1839	,
O	1840	1852	respectively
O	1853	1854	(
O	1854	1857	one
O	1857	1858	-
O	1858	1863	sided
O	1864	1870	Fisher
O	1870	1871	'
O	1871	1872	s
O	1873	1878	exact
O	1879	1883	test
O	1883	1884	,
O	1885	1886	p
O	1887	1888	=
O	1889	1890	0
O	1890	1891	.
O	1891	1894	071
O	1894	1895	)
O	1895	1896	,
O	1897	1900	and
O	1901	1905	that
B-outcome	1906	1908	in
I-outcome	1909	1917	patients
I-outcome	1918	1922	with
I-outcome	1923	1929	triple
I-outcome	1929	1930	-
I-outcome	1930	1938	negative
I-outcome	1939	1945	breast
I-outcome	1946	1952	cancer
O	1953	1956	was
B-iv-bin-percent	1957	1959	35
I-iv-bin-percent	1959	1960	.
I-iv-bin-percent	1960	1961	3
I-iv-bin-percent	1961	1962	%
O	1963	1966	and
B-cv-bin-percent	1967	1969	11
I-cv-bin-percent	1969	1970	.
I-cv-bin-percent	1970	1971	8
I-cv-bin-percent	1971	1972	%
O	1973	1975	in
O	1976	1979	the
O	1980	1983	CTZ
O	1984	1987	and
O	1988	1990	CT
O	1991	1997	groups
O	1997	1998	,
O	1999	2011	respectively
O	2012	2013	(
O	2013	2016	one
O	2016	2017	-
O	2017	2022	sided
O	2023	2029	Fisher
O	2029	2030	'
O	2030	2031	s
O	2032	2037	exact
O	2038	2042	test
O	2042	2043	,
O	2044	2045	p
O	2046	2047	=
O	2048	2049	0
O	2049	2050	.
O	2050	2053	112
O	2053	2054	)
O	2054	2055	.

O	2056	2060	Thus
O	2061	2064	the
O	2065	2073	addition
O	2074	2076	of
O	2077	2080	ZOL
O	2081	2083	to
O	2084	2095	neoadjuvant
O	2096	2098	CT
O	2099	2102	has
O	2103	2112	potential
O	2113	2123	anticancer
O	2124	2132	benefits
O	2133	2135	in
O	2136	2150	postmenopausal
O	2151	2159	patients
O	2160	2163	and
O	2164	2172	patients
O	2173	2177	with
O	2178	2184	triple
O	2184	2185	-
O	2185	2193	negative
O	2194	2200	breast
O	2201	2207	cancer
O	2207	2208	.

O	2209	2216	Further
O	2217	2230	investigation
O	2231	2233	is
O	2234	2243	warranted
O	2243	2244	.

O	2245	2255	University
O	2256	2264	Hospital
O	2265	2272	Medical
O	2273	2284	Information
O	2285	2292	Network
O	2292	2293	.

O	2294	2307	UMIN000003261
O	2307	2308	.
